Skip to main content
Premium Trial:

Request an Annual Quote

IBM, Accelrys Collaboration Now Extends to Data Storage

BOSTON, Oct. 3 - IBM and Accelrys are set to announce an extension of a nine-month-old collaboration that will bring together Big Blue's TotalStorage and Tivoliproducts with Accelrys' new Discovery Studio product line, officials from both companies said today.


The agreement, which makes IBM Accelrys' preferred storage provider, will also complement IBM's tape, disk, and networked storage architectures, and software for centralized storage management.


No customers have yet signed on, according to Steven Levine, senior director of strategic partnerships at Accelrys. Levine added that the partners will share engineering responsibilities as well as sales and marketing tasks.


In January, IBM and Accelrys formed a wide-ranging drug-discovery hardware and software technology and marketing alliance. The partnership, slated to last four years, will pair Accelrys' drug-discovery software with IBM's server technology.


As part of that agreement, IBM also became Accelrys' preferred-technology partner for life sciences, and its eServer systems will be the company's standard server. The Pharmacopeia subsidiary will use the IBM Regatta p690 system, the xSeries systems for Linux and Windows NT and, the eServer Cluster 1300 system for Linux.


The two companies will jointly market drug-discovery computer technology, including Accelrys' planned Discovery Studio platform, intended to integrate the entire process of drug discovery and development. IBM's DiscoveryLink data integration technology will be part of this new platform. (As a side note, Accelrys this week launched a proteomics component of its Discovery Studio line, called DS Modeling.)


The initial deal enabled Accelrys' drug-discovery applications to run optimally on eServer systems. Accelrys also becomes a "premier partner" in IBM's "PartnerWorld for Developers Program," giving it top-drawer status as an IBM partner and access to the computer giant's sales, education, training and technical support programs.


The alliance is "one of the most significant and influential relationships for IBM in life sciences," said IBM Life Sciences general manager Caroline Kovac in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.